Smith+Nephew has commercially launched its Lynx Coblation Laryngeal Wand, a device developed for ear, nose and throat (ENT) surgeons carrying out laryngology procedures.

The wand is designed with input from laryngologists to offer flexibility and clinical performance in airway surgeries, ranging from the supraglottis to the trachea.

It has features intended to support surgeons' needs for versatility, such as an extended working length, malleable shaft and options for both fine dissection and mass debulking.

The device operates at lower temperatures than CO₂ or potassium titanyl phosphate (KTP) lasers.

Smith+Nephew highlighted that the wand’s self-clearing function is designed to reduce blockages during procedures.

It also permits radial incisions of target tissue in all directions and can be adapted to fit patient anatomy.

Referring to the device’s application, Smith+Nephew said the Lynx Coblation Laryngeal Wand is suitable for ablation, resection, and coagulation of soft tissues, as well as haemostasis of blood vessels.

Smith+Nephew’s ENT senior vice-president and general manager Meghan Mavity said: “Early feedback from surgeons using the Lynx Coblation Laryngeal Wand has been impressive.

“We listened to what ENT surgeons wanted and designed something specifically for them. The result is an exceptionally versatile laryngeal wand that fills an unmet need — a single, streamlined surgical solution for airway procedures.”

The Lynx Wand joins Smith+Nephew’s portfolio of Coblation ENT Technology products, which have seen more than 20 years of clinical use.

This technology is described as a method of tissue removal using plasma at lower temperatures compared to some laser systems.

In April 2026, Smith+Nephew reported that its Cartiheal Agili-C cartilage repair implant produced a higher Knee injury and Osteoarthritis Outcome Score (KOOS) compared to standard surgical care at five years in a multi-centre, randomised controlled trial.